BioNTech SE (BNTX) Operating Leases (2018 - 2025)
BioNTech SE (BNTX) posted Operating Leases of $268.1 million for Q4 2025, down 1.31% sequentially from $271.6 million in Q4 2024, and down 1.31% YoY from $271.6 million in Q4 2024.
BioNTech SE (BNTX) Operating Leases (2018 - 2025) Analysis & Trends
BioNTech SE has reported Operating Leases for 7 years, with the latest figure at $268.1 million in Q4 2025.
- Quarterly Operating Leases fell 1.31% year-over-year to $268.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $268.1 million (down 1.31% YoY) and the FY2025 annual result came in at $260.2 million, down 4.21% from the prior year.
- Operating Leases declined to $268.1 million in Q4 2025 per BNTX's latest filing, from $271.6 million in the prior quarter.
- Over five years, Operating Leases peaked at $271.6 million in Q4 2024 and troughed at $207.7 million in Q4 2021.
- A 5-year average of $236.3 million and a median of $228.0 million in 2023 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2024 and 2025: Operating Leases climbed 16.5% in 2024, then slipped 1.31% in 2025.
- Over 5 years, Operating Leases stood at $207.7 million in 2021, then gained by 3.18% to $214.4 million in 2022, then rose by 8.77% to $233.2 million in 2023, then rose by 16.5% to $271.6 million in 2024, then slipped by 1.31% to $268.1 million in 2025.
- According to Business Quant data, Operating Leases over the past three periods registered $268.1 million, $271.6 million, and $233.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Roivant Sciences | 26.52 Bn | 26.52 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 268.08 Mn |
| Dec 31, 2024 | 271.64 Mn |
| Dec 31, 2023 | 233.16 Mn |
| Mar 31, 2023 | 222.93 Mn |
| Dec 31, 2022 | 214.35 Mn |
| Dec 31, 2021 | 207.75 Mn |
| Sep 30, 2019 | 64.17 Mn |
| Dec 31, 2018 | 57.93 Mn |